Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Boswellic acid has anti-inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells.

Barbarisi M, Barbarisi A, De Sena G, Armenia E, Aurilio C, Libutti M, Iaffaioli RV, Botti G, Maurea N, Quagliariello V.

Phytother Res. 2019 Jun;33(6):1670-1682. doi: 10.1002/ptr.6354. Epub 2019 Mar 28.

PMID:
30924205
2.

Combination therapy for the treatment of pancreatic cancer through hyaluronic acid-decorated nanoparticles loaded with quercetin and gemcitabine: A preliminary in vitro study.

Serri C, Quagliariello V, Iaffaioli RV, Fusco S, Botti G, Mayol L, Biondi M.

J Cell Physiol. 2019 Apr;234(4):4959-4969. doi: 10.1002/jcp.27297. Epub 2018 Oct 18.

PMID:
30334571
3.

Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity.

Quagliariello V, Vecchione R, Coppola C, Di Cicco C, De Capua A, Piscopo G, Paciello R, Narciso V, Formisano C, Taglialatela-Scafati O, Iaffaioli RV, Botti G, Netti PA, Maurea N.

Nutrients. 2018 Sep 14;10(9). pii: E1304. doi: 10.3390/nu10091304.

4.

Corrigendum to "Association of Ozone with 5-Fluorouracil and Cisplatin in Regulation of Human Colon Cancer Cell Viability: In Vitro Anti-Inflammatory Properties of Ozone in Colon Cancer Cells Exposed to Lipopolysaccharides".

Simonetti V, Quagliariello V, Giustetto P, Franzini M, Iaffaioli RV.

Evid Based Complement Alternat Med. 2018 Apr 30;2018:3297906. doi: 10.1155/2018/3297906. eCollection 2018.

5.

Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.

Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, Tamburini E, Di Costanzo F, Tonini G, Bilancia D, Corsi D, Pisconti S, Ferrau F, Gori S, Daniele B, Zaniboni A, Soto Parra H, Frassinetti GL, Iaffaioli RV, Cassata A, Zampino MG, Repetto L, Calegari MA, Barone C; all the investigators of ERMES study group.

Future Oncol. 2018 Jun;14(14):1339-1346. doi: 10.2217/fon-2017-0592. Epub 2018 May 30.

PMID:
29846100
6.

Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Romano FJ, Piscitelli R, Iovane G, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, Iaffaioli RV, Facchini G.

Oncotarget. 2017 Sep 22;8(37):62816. doi: 10.18632/oncotarget.20631. eCollection 2017 Sep 22.

7.

Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.

Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F; GISCAD investigators.

Eur J Cancer. 2017 Sep;83:106-115. doi: 10.1016/j.ejca.2017.06.029. Epub 2017 Jul 20.

PMID:
28735067
8.

Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Romano FJ, Piscitelli R, Iovane G, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, Iaffaioli RV, Facchini G.

Oncotarget. 2017 May 2;8(18):30606-30616. doi: 10.18632/oncotarget.16725. Review. Erratum in: Oncotarget. 2017 Sep 22;8(37):62816.

9.

Anticancer and Anti-Inflammatory Properties of Ganoderma lucidum Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment.

Barbieri A, Quagliariello V, Del Vecchio V, Falco M, Luciano A, Amruthraj NJ, Nasti G, Ottaiano A, Berretta M, Iaffaioli RV, Arra C.

Nutrients. 2017 Feb 28;9(3). pii: E210. doi: 10.3390/nu9030210.

10.

Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey.

Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi A, Nasti G, Fisichella R, Romano C, De Divitiis C, Taibi R, Fiorica F, Di Francia R, Di Mari A, Del Pup L, Crispo A, De Paoli P, Santorelli A, Quagliariello V, Iaffaioli RV, Tirelli U, Facchini G.

Oncotarget. 2017 Apr 11;8(15):24401-24414. doi: 10.18632/oncotarget.14224.

11.
12.

Surface modified zeolite-based granulates for the sustained release of diclofenac sodium.

Serri C, de Gennaro B, Quagliariello V, Iaffaioli RV, De Rosa G, Catalanotti L, Biondi M, Mayol L.

Eur J Pharm Sci. 2017 Mar 1;99:202-208. doi: 10.1016/j.ejps.2016.12.019. Epub 2016 Dec 22.

PMID:
28012939
13.

Hyaluronic Acid Nanohydrogel Loaded With Quercetin Alone or in Combination to a Macrolide Derivative of Rapamycin RAD001 (Everolimus) as a New Treatment for Hormone-Responsive Human Breast Cancer.

Quagliariello V, Iaffaioli RV, Armenia E, Clemente O, Barbarisi M, Nasti G, Berretta M, Ottaiano A, Barbarisi A.

J Cell Physiol. 2017 Aug;232(8):2063-2074. doi: 10.1002/jcp.25587. Epub 2017 Mar 1.

PMID:
27607841
14.

Effect of pulsed electric fields - assisted extraction on anti-inflammatory and cytotoxic activity of brown rice bioactive compounds.

Quagliariello V, Iaffaioli RV, Falcone M, Ferrari G, Pataro G, Donsì F.

Food Res Int. 2016 Sep;87:115-124. doi: 10.1016/j.foodres.2016.07.005. Epub 2016 Jul 7.

PMID:
29606232
15.

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.

Rachiglio AM, Esposito Abate R, Sacco A, Pasquale R, Fenizia F, Lambiase M, Morabito A, Montanino A, Rocco G, Romano C, Nappi A, Iaffaioli RV, Tatangelo F, Botti G, Ciardiello F, Maiello MR, De Luca A, Normanno N.

Oncotarget. 2016 Oct 11;7(41):66595-66605. doi: 10.18632/oncotarget.10704.

16.

Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.

Trotta AM, Ottaiano A, Romano C, Nasti G, Nappi A, De Divitiis C, Napolitano M, Zanotta S, Casaretti R, D'Alterio C, Avallone A, Califano D, Iaffaioli RV, Scala S.

Cancer Immunol Res. 2016 Apr;4(4):366-74. doi: 10.1158/2326-6066.CIR-15-0184. Epub 2016 Jan 27.

17.

Submicron complex lipid carriers for curcumin delivery to intestinal epithelial cells: Effect of different emulsifiers on bioaccessibility and cell uptake.

Yucel C, Quagliariello V, Iaffaioli RV, Ferrari G, Donsì F.

Int J Pharm. 2015 Oct 15;494(1):357-69. doi: 10.1016/j.ijpharm.2015.08.039. Epub 2015 Aug 17.

PMID:
26291881
18.

[Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].

De Divitiis C, Cassata A, Nasti G, Ottaiano A, Nappi A, Barretta ML, Iaffaioli RV.

Recenti Prog Med. 2015 Aug;106(8):e407-13. doi: 10.1701/1960.21312. Italian.

PMID:
26228865
19.

Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.

Capozzi M, Caterina I, De Divitiis C, von Arx C, Maiolino P, Tatangelo F, Cavalcanti E, Di Girolamo E, Iaffaioli RV, Scala S, Tafuto S; ENETS Center of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy).

Int J Surg. 2015 Sep;21 Suppl 1:S89-94. doi: 10.1016/j.ijsu.2015.06.064. Epub 2015 Jun 27. Review.

20.

A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report.

De Divitiis C, von Arx C, Carbone R, Tatangelo F, Di Girolamo E, Romano GM, Ottaiano A, de Lutio di Castelguidone E, Iaffaioli RV, Tafuto S.

Onco Targets Ther. 2015 Mar 31;8:669-75. doi: 10.2147/OTT.S71025. eCollection 2015.

Supplemental Content

Loading ...
Support Center